Source: Annual Congress 2006 - Evaluation of drugs for the treatment of lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papi, P. Paggiaro, J. Zarkovic, G. Nicolini, L. M. Fabbri (Ferrara, Pisa, Parma, Modena, Italy; Vienna, Austria). Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma. Eur Respir J 2006; 28: Suppl. 50, 2534

Member's Comments

No comment yet.

Related content which might interest you: Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004 Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003 Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001 A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001 Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Source: Eur Respir J 2007; 29: 682-689 Year: 2007 Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007 Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003 Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002 A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003 Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids? Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003